Verity Asset Management adds Bristol-Myers Squibb Co (BMY) to its portfolio

Bristol-Myers Squibb Co (BMY) : Verity Asset Management added new position in Bristol-Myers Squibb Co during the most recent quarter end. The investment management firm now holds 23,682 shares of Bristol-Myers Squibb Co which is valued at $1,339,454 , the company said in a statement filed on Nov 14, 2016 with the SEC.Bristol-Myers Squibb Co makes up approximately 1.25% of Verity Asset Management’s portfolio.

Other Hedge Funds, Including , Capital Analysts boosted its stake in BMY in the latest quarter, The investment management firm added 6,222 additional shares and now holds a total of 37,675 shares of Bristol-Myers Squibb Co which is valued at $2,130,898. Bristol-Myers Squibb Co makes up approx 0.41% of Capital Analysts’s portfolio.Pbwm Holdings boosted its stake in BMY in the latest quarter, The investment management firm added 1,500 additional shares and now holds a total of 12,171 shares of Bristol-Myers Squibb Co which is valued at $620,843. Bristol-Myers Squibb Co makes up approx 0.24% of Pbwm Holdings’s portfolio.Pettee Investors reduced its stake in BMY by selling 904 shares or 1.61% in the most recent quarter. The Hedge Fund company now holds 55,397 shares of BMY which is valued at $2,801,426. Bristol-Myers Squibb Co makes up approx 2.82% of Pettee Investors’s portfolio.Seaward Management Limited Partnership reduced its stake in BMY by selling 800 shares or 0.95% in the most recent quarter. The Hedge Fund company now holds 83,261 shares of BMY which is valued at $4,125,583. Bristol-Myers Squibb Co makes up approx 0.22% of Seaward Management Limited Partnership’s portfolio.Koshinski Asset Management reduced its stake in BMY by selling 1,922 shares or 18.7% in the most recent quarter. The Hedge Fund company now holds 8,357 shares of BMY which is valued at $415,928. Bristol-Myers Squibb Co makes up approx 0.21% of Koshinski Asset Management’s portfolio.

Bristol-Myers Squibb Co opened for trading at $56.58 and hit $56.84 on the upside on Monday, eventually ending the session at $56.76, with a gain of 0.14% or 0.08 points. The heightened volatility saw the trading volume jump to 73,87,424 shares. Company has a market cap of $94,859 M.

On the company’s financial health, Bristol-Myers Squibb Co reported $0.77 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on Oct 27, 2016. Analyst had a consensus of $0.65. The company had revenue of $4922.00 million for the quarter, compared to analysts expectations of $4796.98 million. The company’s revenue was up 21.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.39 EPS.

Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Shares were Reiterated by Deutsche Bank on Oct 28, 2016 to “Hold” and Lowered the Price Target to $ 52 from a previous price target of $59 .Shares were Reiterated by Barclays on Sep 9, 2016 to “Equal Weight” and Lowered the Price Target to $ 65 from a previous price target of $75 .

Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.

Leave a Reply

Bristol-Myers Squibb Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Bristol-Myers Squibb Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.